XML 32 R20.htm IDEA: XBRL DOCUMENT
v3.19.1

License, Clinical Trial and Sponsored Research Agreements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2018
License Agreement Disclosure [Abstract] |
Research and Development Arrangement, Contract to Perform for Others [Table Text Block] | For the years ended December 31, 2018 and 2017, the Company recorded the following expense in research and development for licenses acquired:
|  | For the year ended December 31, |
($ in thousands) |  | 2018 |  |  | 2017 |
City of Hope |  |  |  |  |  |  |  |
Manufacturing |  | $ | 75 |  |  | $ | - |
IL13Rα2 |  |  | - |  |  |  | 500 |
IV/ICV |  |  | - |  |  |  | 125 |
PSCA |  |  | - |  |  |  | 300 |
HER2 |  |  | 200 |  |  |  | 600 |
CS1 |  |  | - |  |  |  | 600 |
Harvard University - CRISPR |  |  | - |  |  |  | 250 |
UCLA |  |  | - |  |  |  | 200 |
Fred Hutch - CD20 |  |  | - |  |  |  | 300 |
St. Jude - XSCID |  |  | 1,000 |  |  |  | - |
Fortress PIK Dividend |  |  | 2,085 |  |  |  | 9,558 |
Total |  | $ | 3,360 |  |  | $ | 12,433 |
For the years ended December 31, 2018 and, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:
|  | For the year ended December 31, |
|  | 2018 |  |  | 2017 |
($ in thousands) |  |  |  |  |  |
City of Hope |  | $ | 2,000 |  |  | $ | 2,000 |
City of Hope - CD123 |  |  | 835 |  |  |  | 1,227 |
City of Hope - IL13Rα2 |  |  | 1,056 |  |  |  | 1,578 |
City of Hope - Manufacturing |  |  | 458 |  |  |  | - |
Fred Hutch - CD20 |  |  | 1,301 |  |  |  | 614 |
BIDMC - CRISPR |  |  | 69 |  |  |  | 138 |
Total |  | $ | 5,719 |  |  | $ | 5,557 |

X
- References No definition available. + Details
Name: | mbio_LicenseAgreementDisclosureAbstract
Namespace Prefix: | mbio_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration